Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 629.58M P/E - EPS this Y 46.00% Ern Qtrly Grth -
Income -217.42M Forward P/E -2.76 EPS next Y 37.70% 50D Avg Chg 8.00%
Sales 106.39M PEG -0.46 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.50 EPS next 5Y 9.80% 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 9.32 Shares Outstanding 115.76M 52W Low Chg 41.00%
Insider Own 2.12% ROA -28.62% Shares Float 89.21M Beta 1.18
Inst Own 109.17% ROE -119.24% Shares Shorted/Prior 21.69M/19.26M Price 10.25
Gross Margin 92.99% Profit Margin -204.36% Avg. Volume 1,262,433 Target Price 18.83
Oper. Margin -63.79% Earnings Date Aug 6 Volume 568,776 Change -3.03%
About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc. News
05/15/24 Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
05/15/24 Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
05/14/24 Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
05/13/24 Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
05/03/24 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/29/24 Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04/26/24 Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts
04/24/24 Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
04/10/24 Arcutis Appoints David Topper as Chief Financial Officer
04/08/24 Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
04/01/24 Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
03/28/24 Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
08:55 AM Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
08:40 AM Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
03/18/24 Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
03/11/24 Arcutis Promotes Todd Tucker to Chief Human Resources Officer
03/10/24 Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
03/09/24 New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
03/08/24 Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors
03/04/24 Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
ARQT Chatroom

User Image AZNEWCASTLE Posted - 33 minutes ago

$ARQT On Schwab app it says 104.04 % institution owned? What does that mean? Didn't think a number like that was possible. Was a shade over 92% last week. Hmmm?

User Image PsychoNut Posted - 1 day ago

@AZNEWCASTLE heh. F ICU! Let's go $ARQT!

User Image lyonsa14 Posted - 1 day ago

$ARQT Please ignore my message below, this was meant for a different stock, and I can’t seem to delete this for some reason.

User Image PsychoNut Posted - 1 day ago

$ARQT two insider sales but they're restricted stock vest. Automated sales.

User Image lyonsa14 Posted - 1 day ago

$ARQT SEC should investigate. They’re clearly sleeping at the wheel and I’m going to be very hesitant going forward investing in small biotech given that it’s not a level playing field for small investors.

User Image InvCom Posted - 1 day ago

$ARQT I know that many short sellers close theirs positions on Friday to reduce short position holding cost over the weekend. So we could see today little pump

User Image InvCom Posted - 1 day ago

$ARQT Holding 2100 shares with +7%. Keep going ARQT!

User Image PsychoNut Posted - 1 day ago

$ARQT this dude is going to hell and he knows it! Iammafluktard!! Look thru his 4 posts and replies... account just to gobble cheap shares and sell short and short again. Whats next? Let it go up dumbass to 11 again then add 300k. Call ur butt buddy spoiled brats sex dungeon buddies to help bring it back down to 8.50s again. I will not break for this guy!! Or anyone from his beastiality sex dungeons!!

User Image PsychoNut Posted - 1 day ago

$ARQT what pisses me off is you know he buys on another brokerage account... he comes in here and taught to get peeps to sell. He lowered the cost after hours yesterday by like .40 to shake people out. What a piece of dog sh!t! I'll post his name next post. If you sell this dumpster c#nt of the devils but sac a single share I will send you to hell myself! Not a dime! I'd strangle a dolphin before I'd give u a single red cent! And I love porpoise! Blow hole... time for a dab! Oh ya I'll post skunt k#nts SN next post. Not 1 share!!! Never never never!!!! Douche...

User Image PsychoNut Posted - 1 day ago

$ARQT green awesome

User Image zawojak Posted - 1 day ago

$ARQT $12 in July

User Image ZManicItalian Posted - 1 day ago

$ARQT just needs a little push, work it bulls

User Image Rhody27 Posted - 2 days ago

$ARQT MMs are working hard to bring this down. I'm not selling.

User Image MurphyDog1 Posted - 2 days ago

$ARQT Let’s see…MM’s, short sellers, poor management…the reasons for the current SP is varied and numerous. How ’bout…A current SP of $9, at a PE of say…15-1, would require an EPS of around $.60. At a Gross to Net factor in the low 60’s (my understanding from the recent broadcast), an annual net profit per share of $.60 would require (based on approx 110m OS shares- somewhere in the area of $150m-175m in annual revenue. Not quite there yet. The anticipated successful outcome of the “generic” court suit, the approval of additional Insurance providers, approval of medicare/ medicaid, the continued PR/ sales rep penetration/awareness with medical providers and the anticipated FDA approval for Atopical Dermatitis application- will all play a part in generating increased revenues. As the GtN number decreases-first into the 50’s and then continuing lower- the SP increase should be dramatic. Try not to focus on the day to day movement…but rather a 1 year or longer horizon. All, IMHO.Good luck !

User Image OracleofAZ Posted - 2 days ago

$ARQT Nothing to worry about here. Sales are killing it and will only get better. By years end we are 20$+.

User Image Chasetae Posted - 2 days ago

$ARQT $8.58 didn’t fill wth. Friday fuckery. MM’s shaken the trees. Oh well happy Friday!

User Image NobVega Posted - 2 days ago

$ARQT Add 400 shares. Was going for 1,000 but it took off. Picked up 1900 more $SOUN. Waiting for scripts on $XERS . Anything over 5,000 for the week could move the needle 15-20 cents.

User Image Father_Christmas Posted - 2 days ago

not worried about $ARQT ... also trading at 90% below fair value according to https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics

User Image nastento Posted - 2 days ago

$ARQT LOL what? They're delivering, that's what they are doing. They're sitting at a 900mil MC..

User Image zawojak Posted - 2 days ago

$ARQT Sorry guys this will be dead and possibly soon sub $8 until July :( it sucks I know, Should have sold at $11 with a small loss. Management does not do anything for shareholders.

User Image Rhody27 Posted - 2 days ago

$ARQT Adding with this MM price manipulation

User Image Slinga_Malinga Posted - 2 days ago

$ARQT complete garbage

User Image ZManicItalian Posted - 2 days ago

$ARQT got my shares in the gap. Now let's slingshot to greeen!

User Image nastento Posted - 2 days ago

$ARQT $10 calls expiring worthless

User Image PsychoNut Posted - 2 days ago

$ARQT options contracts expire tomorrow. Maybe we will see some action.

User Image PsychoNut Posted - 2 days ago

$ARQT this douche added short positions at 10 and 11. Wonder how much change he has in there. He made this account just to taunt people into selling.

User Image AZNEWCASTLE Posted - 2 days ago

$ARQT Did we get bought out or something? Price hasn't moved after hours or maybe I just missed it? I'd be OK with that!

User Image Slinga_Malinga Posted - 2 days ago

$ARQT just fucking hit 10 man

User Image iammariin Posted - 2 days ago

$ARQT

User Image trdranr1a Posted - 3 days ago

$ARQT

Analyst Ratings
Needham Buy May 15, 24
Mizuho Buy May 15, 24
Needham Buy Apr 12, 24
Goldman Sachs Neutral Feb 28, 24
Mizuho Buy Feb 28, 24
Needham Buy Feb 28, 24
Mizuho Buy Feb 23, 24
Mizuho Buy Jan 3, 24
Mizuho Buy Jan 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Burnett Patrick See Remarks See Remarks Jan 02 Sell 3.5408 1,325 4,692 57,032 01/03/24
Watanabe Todd Franklin See Remarks See Remarks May 31 Buy 6.38 1,463 9,334 515,145 12/01/23
Watanabe Todd Franklin See Remarks See Remarks May 31 Option 1.68 59,525 100,002 513,682 12/01/23
Matsuda Masaru See Remark See Remark Nov 18 Sell 1.98 1,850 3,663 46,634 11/21/23
Burnett Patrick See Remarks See Remarks Aug 18 Sell 7.05 1,605 11,315 58,357 08/22/23
Matsuda Masaru See Remark See Remark May 27 Sell 7.8 1,830 14,274 42,146 06/02/23
Welgus Howard G. Director Director Apr 17 Sell 13.97 8,500 118,745 165,825 04/18/23
Welgus Howard G. Director Director Apr 17 Option 1.68 8,500 14,280 174,325 04/18/23
Moore Matthew Richard See Remarks See Remarks Mar 02 Sell 16.17 1,610 26,034 11,690 03/06/23
Matsuda Masaru See Remarks See Remarks Mar 02 Sell 16.17 1,434 23,188 18,101 03/06/23
Burnett Patrick See Remarks See Remarks Mar 02 Sell 16.17 1,751 28,314 39,813 03/06/23
Watanabe Todd Franklin See Remarks See Remarks Feb 28 Sell 16.17 7,815 126,369 369,092 03/02/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.17 1,850 29,915 38,406 03/02/23
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Feb 28 Sell 16.17 2,368 38,291 43,260 03/02/23
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Feb 28 Sell 16.17 2,005 32,421 254,644 03/02/23
Welgus Howard G. Director Director Feb 15 Sell 16.98 8,500 144,330 165,825 02/21/23
Welgus Howard G. Director Director Feb 15 Option 1.68 8,500 14,280 174,325 02/21/23
Watanabe Todd Franklin See Remarks See Remarks Feb 13 Sell 17.02 1,000 17,020 376,907 02/15/23
Welgus Howard G. Director Director Jan 17 Sell 13.72 8,500 116,620 165,825 01/18/23
Welgus Howard G. Director Director Jan 17 Option 1.68 8,500 14,280 174,325 01/18/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Sep 16 Option 1.6806 5,000 8,403 40,256 09/20/22
Watanabe Todd Franklin President and CEO President and CEO Sep 07 Sell 21.51 1,000 21,510 381,907 09/09/22
Welgus Howard G. Director Director Aug 15 Sell 24.7981 6,000 148,789 174,208 08/17/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Option 1.68 2,500 4,200 654,371 08/09/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Sell 24.74 2,500 61,850 651,871 08/09/22
Frazier Life Sciences VIII, L.... 10% Owner 10% Owner Aug 05 Buy 20.00 250,000 5,000,000 8,684,232 08/09/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 23 Option 6.52 15,331 99,958 46,444 08/04/22
Welgus Howard G. Director Director Jul 18 Sell 24.3956 6,000 146,374 180,208 07/18/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Jul 08 Sell 25.4144 2,197 55,835 256,649 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Option 1.68 7,087 11,906 658,958 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Sell 25.28 13,500 341,280 651,871 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 06 Sell 22.07 1,000 22,070 658,284 07/07/22
Watanabe Todd Franklin President and CEO President and CEO May 05 Sell 21.76 1,000 21,760 658,667 05/05/22
Welgus Howard G. Director Director May 02 Option 1.13 2,500 2,825 184,396 05/03/22
Welgus Howard G. Director Director May 02 Sell 20.44 2,500 51,100 181,896 05/03/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Apr 21 Sell 20.4243 2,197 44,872 257,229 04/21/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 06 Sell 20.69 878,200 18,169,958 451,086 04/08/22
Watanabe Todd Franklin President and CEO President and CEO Apr 05 Sell 21.43 1,000 21,430 659,667 04/05/22
Welgus Howard G. Director Director Apr 01 Option 0.58 7,500 4,350 189,396 04/01/22
Welgus Howard G. Director Director Apr 01 Sell 20.02 7,500 150,150 181,896 04/01/22
Watanabe Todd Franklin President and CEO President and CEO Mar 09 Sell 17.00 300 5,100 660,667 03/11/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Option 1.68 700 1,176 661,667 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Sell 16.8 3,259 54,751 660,967 03/07/22
Burnett Patrick See Remarks See Remarks Mar 03 Sell 16.65 1,011 16,833 43,039 03/07/22
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 16.65 1,023 17,033 44,011 03/07/22
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 16.65 303 5,045 35,256 03/07/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 03 Sell 16.65 1,023 17,033 31,113 03/07/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Mar 03 Sell 16.65 856 14,252 259,426 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Option 1.68 1,000 1,680 595,779 02/11/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Sell 17 1,000 17,000 594,779 02/11/22